FDA's AI device review exemption proposal reflects corporate lobbying, regulatory capture, and systemic risks in AI governance
Original framing: “STAT+: A provocative proposal asks the FDA to let some AI devices on the market without review” — STAT News
The proposal’s Orwellian framing—'letting AI devices on the market without review'—disguises corporate capture as 'innovation.' It inverts the precautionary principle, treating patient safety as a barrier to 'progress.' A trickster lens exposes how solemnity around 'AI disruption' conceals extractive exploitation, revealing the absurdity of deregulation in life-critical systems.
The FDA's proposal to exempt AI devices from review reflects a broader pattern of corporate lobbying and regulatory capture, mirroring historical deregulation trends in other sectors.
The absence of Indigenous, cross-cultural, and marginalized voices in the proposal underscores the need for a more inclusive governance framework. Scientific evidence on algorithmic bias and patient safety, along with artistic and spiritual perspectives on AI ethics, must inform future regulations. The solution lies in strengthening FDA oversight with cross-cultural governance, mandating pre-market review for high-risk devices, promoting public-interest AI development, and enforcing transparency in AI governance. Historical precedents, such as the Theranos scandal, demonstrate the consequences of weak oversight, while Indigenous and cross-cultural principles offer alternative models for equitable AI deployment.